This multicenter, prospective, observational, non-interventional study investigates patients with intracranial hemorrhage under effective anticoagulation with dabigatran or vitamin-K antagonist (VKA). Routine data will be collected during hospitalization. Patients aged 18 years or older under effective therapy with dabigatran and symptomatic intracranial bleeding confirmed by cerebral imaging and treated with idarucizumab will be compared to patients under effective treatment with VKA at the time of onset of the intracranial bleeding. Ninety-five dabigatran patients who provided written informed consent for data transmission will be included. As control group retrospective and anonymized data of 285 VKA patients patients under VKA treatment and admitted to RIC-ICH study centers will be used. For each patient receiving idarucizumab, three patients with intracranial hemorrhage under effective treatment with VKA, will be included (retrospective) in the study. In addition, data of VKA patients will be transferred from the RASUNOA-PRIME and the "Erlanger Hirnblutungs-Register".

Start Date19 Sep 2019

Sponsor / Collaborator

University Hospital Of Essen

NCT02798107 / WithdrawnNot Applicable

Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran with very high affinity. Idarucizumab potently and specifically binds to dabigatran and its metabolites and neutralises its anticoagulant effect. A clinical development program is ongoing to support marketing authorisation submissions for idarucizumab indicated in patients treated with dabigatran who require emergency surgery/urgent procedures or who have a life-threatening or uncontrolledbleeding when rapid reversal of the anticoagulant effects of dabigatran is required.

Start Date20 May 2019

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT03359889 / CompletedNot Applicable

Post Marketing Surveillance Program of Praxbind Use in India.

This program will be initiated after the commercial availability of PraxbindTM in India. It will include patients administered with PraxbindTM into the surveillance program after commercial availability in 2 years at selected centres approved by the regulatory authority.

Start Date26 Dec 2018

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Idarucizumab

100 Translational Medicine associated with Idarucizumab

100 Patents (Medical) associated with Idarucizumab

559

Literatures (Medical) associated with Idarucizumab

01 Nov 2024·Heliyon

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report

Article

Author: Costantini, Ilaria ; Losso, Lorenzo ; Bacchion, Matilde ; Drezza, Lucia ; Carollo, Massimo ; Morando, Elia ; Ricci, Giorgio

This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced coagulopathy. An 86-year-old patient, receiving apixaban therapy, presented to the Emergency Department after intentionally ingesting 50 tablets of dabigatran. The combination therapy contributed to the rapid normalization of coagulation parameters and stabilization of the patient's clinical status without subsequent thromboembolic complications. This case adds to the limited evidence on the effectiveness and safety of combining PCC with idarucizumab in cases of multiple anticoagulant intoxication.

21 Oct 2024·Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca

Current Management of Patients with Proximal Femur Fractures Receiving Antiplatelet and Anticoagulant Therapy

Review

Author: Hložník, J ; HLOŽNÍK, J. ; Šteňo, B ; BÁTOROVÁ, A. ; CHANDOGA, I. ; ŠVEC, A. ; Švec, A ; JANKOVIČOVÁ, D. ; PRIGANCOVÁ, T. ; Bátorová, A ; Chandoga, I ; Prigancová, T ; ŠTEŇO, B. ; Jankovičová, D

Proximal femur fractures (PFF) pose a major challenge in elderly patients with severe comorbidities and receiving antithrombotic therapy since according to the latest guidelines the surgery should be performed as soon as possible, preferably within 24 hours, to reduce mortality and morbidity. This review outlines the practical approach to surgical management of PFF that relies on increasing evidence of safety of early surgery in patients with PFF receiving antiplatelet and anticoagulant therapy. We have also used information from the existing evidence-based guidelines for elective/planned surgery in patients with antithrombotic therapy. The practical approach can be summarised as follows: • Antiplatelet therapy - discontinuation of acetylsalicylic acid (ASA) and clopidogrel in monotherapy or in combination is not necessary prior to surgery. In case of bleeding, antifibrinolytic therapy is recommended as well as administration of platelet concentrate which is rarely needed. • In patients taking warfarin, reversal of its effects is recommended by early administration of vitamin K to allow surgery to be performed within 24 hours. Prothrombin complex concentrate (PCC) as a second-line drug is reserved for extreme cases only. Warfarin therapy is resumed 24 hours after surgery. • Direct oral anticoagulants must be discontinued 24-48 hours prior to surgery, possibly longer depending on the type of drug, time of administration of the last dose, and renal function. In extreme cases, an antidote (idarucizumab, off-label andexanet) can be administered prior to surgery, or PCC in case they are unavailable. Anticoagulation therapy is resumed in 24-48 hours. • Neuraxial anaesthesia is possible when ASA is taken by the patient and in case of effective warfarin reversal. • In early surgery and rapid restart of anticoagulant therapy, bridging therapy with LMWH is not indicated except for in cases with extreme risk of thrombosis. Key words: proximal femur fracture, antiplatelet therapy, anticoagulant therapy, perioperative management.

08 Oct 2024·Neurology

Thrombolysis After Dabigatran Reversal for Acute Ischemic Stroke: A National Registry-Based Study and Meta-Analysis.

Review

Author: Plomaritis, Panagiotis ; Giannopoulos, Sotirios ; Bakola, Eleni ; Kiamili, Argyro ; Melanis, Konstantinos ; Psychogios, Klearchos ; Stefanou, Maria-Ioanna ; Ntais, Evangelos ; Safouris, Apostolos ; Chondrogianni, Maria ; Tsivgoulis, Georgios ; Seiffge, David J ; Sarraj, Amrou ; Theodorou, Aikaterini ; Kargiotis, Odysseas ; Palaiodimou, Lina

BACKGROUND AND OBJECTIVESLimited data exist on the safety of IV thrombolysis (IVT) for acute ischemic stroke (AIS) after dabigatran reversal with idarucizumab. We sought to evaluate the safety and efficacy of idarucizumab pretreatment in patients with AIS receiving IVT.METHODSA national registry-based study evaluated the safety and efficacy of IVT in this specific subgroup. We also conducted a systematic review and meta-analysis of cohort studies and case series, aiming to document the pooled rates of (1) symptomatic intracranial hemorrhage (sICH), (2) any intracranial hemorrhage, (3) 3-month mortality, and (4) the proportion of excellent (modified Rankin Scale [mRS] scores 0-1) and (5) good (mRS scores 0-2) functional outcome at 3 months among patients with AIS, who received IVT after dabigatran reversal with idarucizumab. Moreover, we sought to compare these outcomes between IVT-treated patients after dabigatran reversal with idarucizumab and IVT-treated patients without dabigatran pretreatment.RESULTSThirteen cohorts including our nation-wide registry-based cohort and 1 case series comprising 553 patients with AIS (mean age: 75 years; male sex: 65%; median baseline NIH Stroke Scale score: 11 points) receiving idarucizumab before IVT were included in this meta-analysis. The pooled rate of sICH after IVT after idarucizumab administration was 4% (95% CI 1-9; I² = 26%), while the pooled rates of any intracranial hemorrhage and 3-month mortality were 10% (95% CI 5-16; I² = 24%) and 18% (95% CI 10-27; I² = 0%), respectively. The pooled rates of excellent and good functional outcomes at 3 months were 56% (95% CI 27-83; I² = 69%) and 70% (95% CI 57-81; I² = 40%), respectively. The risk of sICH (risk ratio [RR] 1.86; 95% CI 0.91-3.80; I² = 0%), any intracranial hemorrhage (RR 1.76; 95% CI 0.99-3.11; I² = 8%), and 3-month mortality (RR 1.50; 95% CI 0.91-2.48; I² = 0%) did not differ between patients with AIS receiving IVT with and without idarucizumab. Moreover, idarucizumab administration was associated with higher likelihood of achieving a 3-month good functional outcome (RR 1.35; 95% CI 1.11-1.65; I² = 27%).DISCUSSIONIVT for AIS after dabigatran reversal with idarucizumab seems to be safe and effective in observational studies with limited number of patients. Randomized-controlled clinical trials are warranted to provide robust evidence on the safety and efficacy of IVT in this specific AIS subgroup.

News (Medical) associated with Idarucizumab

11 Sep 2024

·www.biospace.com

Feinstein Institutes Research Suggests New Management Protocols for Patients Taking Oral Anticoagulants

MANHASSET, N.Y.--(BUSINESS WIRE)--Direct oral anticoagulants (DOACs) are commonly used medications that help prevent blood clots, which can be dangerous for those suffering from heart conditions or at risk of venous thromboembolism. However, these medications can also increase the likelihood of bleeding, especially during surgeries. Researchers at the Feinstein Institutes for Medical Research recently published in the Journal of the American Medical Association (JAMA) protocols to effectively manage the administration of DOACs and minimize bleeding and clotting risks – suggesting new conventions for patients pre- and post-surgery. Approximately 4 million patients in the United States are currently being treated with DOAC therapy. The review paper, titled “Perioperative Management of Patients Taking Direct Oral Anticoagulants,” analyzed how physicians should handle a patient’s blood thinner medicine depending on whether a procedure is surgical and to what degree of risk a procedure presents. The paper reviewed 99 articles on blood thinners and surgery to inform its evaluation. The authors concluded that doctors must assess the bleeding risk (low, medium, or high) of a planned surgery. Additionally, the research recommends that standardized management protocols – which do not require testing DOAC levels, heparin bridging, or short-acting anticoagulants – can be safely and effectively used for patients undergoing elective or non-urgent procedures. However, for patients on DOACs who require emergency, urgent, or semi-urgent surgery, using anticoagulant reversal agents may be appropriate if DOAC levels are elevated or unavailable. “When patients taking DOAC blood thinners undergo an optional or nonsurgical procedure, doctors can follow a simple standardized management plan where they won’t need to administer a blood test to check DOAC levels or use heparin, an alternate blood thinner,” said Alex C. Spyropoulos, MD , professor at Feinstein Institutes’ Institute of Health System Science . “Through this careful review, we determine that urgent or emergent procedures are another story and may need additional therapy and monitoring to prevent complications.” Patients who require urgent or emergency surgeries may need additional medications that quickly reverse the effects of DOACs if bleeding occurs during the procedure. One type of reversal agent (examples include andexanet-α for edoxaban, rivaroxaban , or apixaban and idarucizumab for dabigatran) can help with specific DOACs, while a more general reversal agent called prothrombin complex concentrate (PCC) can reverse the effects of any DOAC medication, albeit less effectively. “A leader in the field, Dr. Spyropoulos advances patient care through his research,” said Kevin J. Tracey, MD , president and CEO of the Feinstein Institutes and the Karches Family Distinguished Chair in Medical Research at Northwell Health. “His new insights into preventing life-threatening blood clots during elective procedures have the potential to benefit countless patients at Northwell Health and globally.” In addition to this JAMA article, and investigating a blood clot prevention treatment called thromboprophylaxis – particularly in relation to the treatment of hospitalized COVID-19 patients – Dr. Spyropoulos and his co-authors recently published an article in the Journal of Thrombosis and Haemostasis that determined hospitals’ incorporation of a user-friendly clinical decision support tool can also significantly improve the appropriate use of blood clot prevention strategies. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, translational research, and molecular medicine. We make breakthroughs in health condition, including endometriosis, lupus, postpartum depression, schizophrenia, sepsis. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn . Contacts Matthew Libassi 631-793-5325 mlibassi@northwell.edu

17 Aug 2022

·www.biospace.com

High Prevalence Of Respiratory Disorders Is Expected To Boost Growth Prospects For High-Flow Nasal Cannula Market During The Forecast Period

The Acute Respiratory Failures Segment Is Expected To Grow Impressively At A CAGR Of 11.4% Fact.MR – A Market Research and Competitive Intelligence Provider: The global high-flow nasal cannula market is expected to witness a CAGR of 11.8% during the forecast period (2020 – 2025). Technological advancements by key market players are also expected to offer opportunities and new avenues for the market. High prevalence of acute respiratory failures is expected to offer lucrative opportunities for high-value oxygen therapy using high-flow nasal cannula. Other benefits of high-flow nasal cannula are that they deliver a consistent flow of oxygen via the nasal cannula and alleviate upper airway obstruction. Moreover, rise in prevalence of sleep apnea is also anticipated to boost the market growth. High prevalence of non-invasive ventilation and continuous positive airway pressure devices has risen rapidly in home care settings for patients suffering from respiratory diseases. This has also pushed key manufacturers to increase production of devices, thus boosting the market share. For more insights into the Market, Request Brochure of this Report Moreover, increasing population, growing smoking prevalence and degraded air quality have boosted the number of respiratory disease cases. Key players in the market are expanding its production of respiratory support, ventilators and humidification products to hospitals. For instance, ResMed has boosted the production of its devices such as AirCurve 10 bi-level devices to offer some comfort to Covid-19 patients. Key Takeaways: The Acute Respiratory Failures segment is expected to account for around 3/10th of the high-flow nasal cannula market, growing rapidly at a CAGR of 11.4% Rising prevalence of sleep apnea is also expected to boost the market of high-flow nasal cannula. Moreover, market is projected to witness a CAGR of 13.5% during the forecast period. Asia pacific is expected to show impressive growth prospects fro the high-flow nasal cannula market. Moreover, Asia pacific is also expected capture a market share of13.2% Growth Drivers: Covid-19 pandemic has boosted the market aspects for high-flow nasal cannula market. Moreover, owing to its widespread application in the treatment of respiratory diseases, high-flow nasal cannula is gaining traction. Also, as the Covid-19 affects the lungs, high-flow nasal cannula is suitable approaches to aid patients breathe normally. Rising prevalence of respiratory diseases is anticipated to boost the high-flow nasal cannula market during the forecast period. Moreover, growing smoking prevalence have also increased the number of respiratory diseases cases across the globe. Growing acceptance of high-flow nasal cannula treatment among various patients is expected to boost the growth of the market Key players in the market are making significant investments in the product portfolio. Companies are significantly investing in technological advancements to acquire market share. Surge in cases of sleep apnea is also expected to boost the growth of high-flow nasal cannula. For Comprehensive Insights Ask An Analyst Here Competitive Landscape: The global high-flow nasal cannula market is fragmented. Out of the major key players, four of these account for the maximum share, three-tenth of the total market. These four players are BD/CareFusion, Fisher & Paykel Healthcare Limited, Telefax incorporated, and ResMed Inc. Moreover, these players are significantly innovating product portfolios by investing into technological advancements to acquire market presence. For instance, Fisher & Paykel is boosting its production of respiratory support devices, ventilators and humidification products to hospitals. Likewise, ResMed has accelerated its production of its AirCurve 10 bi-level devices to provide some comfort to COVID-19 patients. ResMed Inc. is key player in the market. It offers various products for the treatment of sleep apnea and non-invasive ventilation. Also, flagship products include AirView, ClimateLine Max and myAir for the management of sleep apnea and respiratory disorders. Key Companies Profiled by Fact.MR More Valuable Insights on High-flow nasal cannula market By Component: Air/Oxygen Blend Air Humidifier Single Heated Tube Nasal Cannula Other Consumables By Application: Acute Respiratory Failure Chronic Obstructive Pulmonary Disease (COPD) Carbon Monoxide Toxicity Bronchiectasis Sleep Apnea Other Applications By End-user: Hospitals Long-term Care Centers Ambulatory Care Centers Tomosynthesis Other End-users Key Regions: North America Europe Asia Pacific Latin America Middle East & Africa Get Customization on this Report for Specific Research Solutions Explore Fact.MR’s Coverage on the Healthcare Domain Animal Genetics Market - The development of progressive genetic modification practices is leading to the high production of animals with modified breeds, thereby attracting investments from end users. Antacids Market - Manufacturers in the antacids market are approaching drug formulation techniques through consumer-centric means, in the form of chewable and flavored tablets, to score well in convenience regards. On the back of these factors, the exhaustive study by Fact.MR pegs the global antacids markets to soar to ~US$ 19 Bn by 2025. Antimicrobial Susceptibility Test Market - Rising government initiatives regarding the development of quality hospital infrastructure, on a global level, and surging susceptibility to infectious diseases, are projected to complement the demand for antimicrobial susceptibility tests in diagnostic laboratories and hospitals during the forecast period (2020-2025). Anticoagulant Reversal Drugs Market - Sales of Idarucizumab increased 19% Y-o-Y in 2019 over 2018. However, according to the estimation of a seasoned analyst at Fact.MR, year-over-year sales of the same drug will witness a sharp decrease of 11% in 2026 over 2025. Anticancer Drugs Market - Development of therapeutics with better patient outcomes and lesser side-effects than conventional ones is projected to increase patients’ trust in these drugs, thereby strengthening the growth prospects of the anticancer drugs market. Apheresis Market - Lack of regular blood donors is being countered by private blood collection centres that attract donors through paid plans. In recent times, hospitals are increasing the adoption of apheresis equipment to collect and store required blood components, so as to reduce dependency on private suppliers and blood collection centres. Aptamers Market - Advent of the chemical modification process to increase the nuclease resistance of aptamers, and, in turn, enhance their therapeutic properties creates opportunities galore for players in the aptamer market. Dental 3D Printing Market - Development of customized dental models such as bridges, crowns, implants, and dentures is offering better patient outcomes, and, in turn, boosting the reliance of dentists on printed prosthetics. Behavioural Health Treatment Market - The advent of the on-demand service model underpinning the concepts of tele psychiatry offers the choice to patients to avail home-based treatment services. Besides enhancing the comfort feature, home-based treatment services also offer significant cost benefits and reduced wait times. Assisted Reproductive Technology Market - Studying the relevance of all the crucial dynamics, Fact.MR, in its latest study, forecasts that revenue of the assisted reproductive technology market would witness an annual increase of around 6.3% in 2020. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. 80% of Fortune 1000's trusts us in critical decision making. We provide both qualitative and quantitative research, spanning market forecast, market segmentation, competitor analysis, and consumer sentiment analysis. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter

10 Aug 2022

·www.biospace.com

Surge In Number Of Sports Injuries Incidence Is Expected To Push The Growth Of Platelet-Rich Plasma Market By 10% CAGR During The Forecast Period

Dental Technicians Are Progressively Accepting Digital Dentistry, Which Is Offering Lucrative Opportunities For 3D Printer Manufacturers Fact.MR – A Market Research and Competitive Intelligence Provider: The global platelet-rich plasma market is expected to surpass an impressive valuation of around US $ 1.5 Billion surpassing a CAGR of 12% during the assessment period. Platelet-rich plasma is commonly used in healthcare industry, especially in cosmetic surgeries, and orthopedic surgeries. Moreover, Injuries such as rotator cuff, tendon injuries, tennis elbow, and hamstring among others are treated quickly and effectively with the help of platelet-rich plasma therapy. Historically, the platelet-rich plasma market had witnessed a CAGR of 10% and reached a value of US $ 400 Mn. Moreover, surge in sports injuries have also pushed the demand further in coming years. Besides this, plasma is also rapidly used for treatment of medical conditions such as facelift surgeries and erectile dysfunction. These are some of the new application areas in the platelet-rich plasma market. For More Insights on this Market, Get A Sample Report! Apart from this, platelet-rich plasma therapy is very commonly used in cosmetic surgeries. For instance, this is widely used for tapping growth opportunities in hair and skin care. Also, micro-needling, with the help of platelet-rich plasma injections, offers unfolding opportunities to improve skin-texture and appearance. Key Takeaways: United States is anticipated in dominate the market during the forecast period. Moreover, market is expected to witness a CAGR of 9% until 2031. U.K is projected to be the most profitable market for the plasma across Europe owing to high rise in sports injuries. Moreover, market is projected to expand through 2031 registering a growth of 8% CAGR. India is expected to witness an impressive growth prospects for the market during the forecast period. Surge in uptake is observed due to high prevalence of inflammatory diseases. By End-User, Hospitals are expected to register a 10% CAGR during forecast period. Growth Drivers: Surge in number of patients opting for PRP injections is expected to boost the growth of the market. Restraints: Competitive Landscape: The market is moderately competitive and the landscape comprises of key players that are active in the expansion of the global platelet rich-plasma market during the forecast period. Players are also focusing on various strategies to expand product offerings and expand geographic presence. With advancement in technology, new players are entering the market. In February 2021, Atlas Health Medical Group announced plasma-rich platelets availability to its patients. Moreover, in February 2020, EmCyte completed the acquisition of Cellmedix Holdings LLC, that includes proprietary product system, namely Centrepid Platelet Concentrator. To Gain In-Depth Insights on Platelet-Rich Plasma Market, Request Methodology at Key Companies Profiled by Fact.MR Arthrex, Inc. Johnson & Johnson Zimmer Biomet Holdings, Inc. Exactech, Inc. Stryker Corporation Terumo Medical Corporation Biotest Aktiengesellschaft CSL Ltd More Valuable Insights on Platelet-rich Plasma Market Segmentation of Platelet-rich plasma market Product Type Platelet-Rich Plasma Instruments Pure Platelet-Rich Plasma Kits Leucocyte-Rich Platelet-Rich Plasma Kits Platelet-Rich Fibrin Kits Pure Platelet-Rich Fibrin Kits Application Platelet-Rich Plasma for Orthopedic Surgery Platelet-Rich Plasma for Cosmetic Surgery Platelet-Rich Plasma for General Surgery Platelet-Rich Plasma for Neurosurgery Platelet-Rich Plasma for Other Surgeries End User Platelet-Rich Plasma Therapy in Hospitals Platelet-Rich Plasma Therapy in Orthopedic Clinics Platelet-Rich Plasma Therapy in Dermatology Clinics Platelet-Rich Plasma Therapy by Other End Users Interested to Procure The Data? Inquire here Explore Fact.MR's Coverage on the Healthcare Domain- Antacids Market - Antacids Market Analysis Report By Drug Class (Proton Pump Inhibitors, H2 Antagonists), By Distribution Channel (Hospital, Retain Pharmacies), By Formulation, By Region - Global Market Insights 2020-2025 Antimicrobial Susceptibility Test Market - Antimicrobial Susceptibility Test Market Analysis Repot By Product (Kits, Reagents, & Consumables, Automated Test Systems, Culture Media), By Application (Clinical Diagnosis, Drug Discovery and Development), By End User, By Region - Global Insights 2020-2025 Anticoagulant Reversal Drugs Market - Anticoagulant Reversal Drugs Market Analysis Repot By Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Global Insights 2020-2026 Anticancer Drugs Market - Anticancer Drugs Market Analysis Repot By Drug Type (Targeted Drugs, Cytotoxic Drugs, Hormonal Drugs), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Colorectal Cancer), By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy) - Global Market Forecast 2020-2025 Apheresis Market - Apheresis Market Analysis Repot By Technology (Centrifugation, Membrane Filtration), By Product (Devices, Disposables), By Application (Renal Diseases, Neurology, Haematology, Cancer, Autoimmune Diseases,Cardiovascular Diseases), By Region - Global Market Forecast 2020-2025 Aptamers Market - Aptamers Market Analysis Repot By Application (Research, Diagnostics, Therapeutics), By Selection Technique (SELEX Technique), By Material (Nucleic Acid Aptamers, Peptide Aptamers), By Region - Global Market Forecast to 2010-2025 Dental 3D Printing Market - Dental 3D Printing Market Size, Trend Analysis & Competition Tracking By Material (Metals, Photopolymers, Ceramics), By Application (Dental Implants, Dentures, Crowns & Bridges), By Technology (Vat Photo Polymerization, Fused Deposition Modelling, PolyJet Technology, Selective Laser Sintering) - Global Market Insights 2021 to 2031 Behavioural Health Treatment Market - Behavioural Health Treatment Market Analysis Report By Disorder (Depression, Anxiety, Schizophrenia, Bipolar Disorder, Alcohol Use Disorders, Substance Use Disorders, Eating Disorders, Post-traumatic Stress Disorders), By Service, By Region -Global Forecast 2020-2027 Assisted Reproductive Technology Market - Assisted Reproductive Technology Market Analysis Report By Procedure (Frozen Donor, Frozen Non-donor, Fresh Donor, Fresh Non-donor, Embryo Banking), By Technology (In-vitro Fertilization, Surrogacy, Artificial Insemination), By End User(Fertility Clinics, Hospitals, Other )- Global Market Insights to 2019-2025 Asthma Treatment Market - Asthma Treatment Market Analysis Report By Treatment Type (Long-term Asthma Control Medications, Quick-relief (Rescue) Medications), By Route of Administration(Inhaled, Oral, Intravenous, Subcutaneous), By Region - Global Forecast 2020 to 2027 About Us: Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 Email: sales@factmr.com Tel: +1 (628) 251-158

ImmunotherapyAcquisition

100 Deals associated with Idarucizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10741	Idarucizumab	V03AB37	DB09264

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemorrhage	US	Boehringer Ingelheim Pharmaceuticals, Inc.	16 Oct 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemorrhage	Phase 2	NZ	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	AU	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	CA	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	AR	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	BR	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	RU	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	TW	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	HK	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	IL	Boehringer Ingelheim GmbH	06 May 2014
Hemorrhage	Phase 2	MX	Boehringer Ingelheim GmbH	06 May 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISTH2023	Not Applicable	-	3,465	Idarucizumab	(bzxqppmzhl) = hvmlrtaawn mecapcfygb (avrzgdfsyj, 11.5 - 19.6) View more	-	24 Jun 2023
ISTH2022	Not Applicable	-	6	Idarucizumab	(msnbfqnmrt) = zjgmzmmwov dkpdhjnbok (pukudtumie ) View more	Positive	09 Jul 2022
ISTH2022	Not Applicable	-	101	Idarucizumab	tommtzmrhu(apzwzpstiv) = lihyftmuyv ulxzgvvtjq (sygktrkijf )	-	09 Jul 2022
ISTH2022	Not Applicable	-	46	Idarucizumab	(iogavnbmdm) = wlzstouuaf psjeeyrbgl (yhcnwtgkcp )	-	09 Jul 2022
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group A - Patients With Uncontrolled or Life-threatening Bleeding)	wvupyjafel(lwziwansds) = csgpcgrhao xtxyjglmki (qumwryufqp, oofeeorzzl - frlmazgjlb) View more	-	20 Aug 2021
NCT03343704 (CTgov)	Phase 3	Hemorrhage	19	Idarucizumab (Group B - Patients Not Bleeding But Requiring Emergency Surgery or Invasive Procedure)	wvupyjafel(lwziwansds) = tftfhjuxom xtxyjglmki (qumwryufqp, jbshfigpvy - vdrfttiowz) View more	-	20 Aug 2021
ISC2021	Not Applicable	Hemorrhage	-	Idarucizumab	(snpnnzczfu) = aovyjrhukm almccdzugc (ytbcjwnnog )	-	01 Mar 2021
ISC2021	Not Applicable	Hemorrhage	-	Andexanet Alfa	(snpnnzczfu) = uloacnwthe almccdzugc (ytbcjwnnog )	-	01 Mar 2021
ESC2020	Not Applicable	-	-	Idarucizumab	(xqiktlnhtg) = ozicfkqlzt vfgifxphzq (rsgvytmdhb, 3.4 - 5.0) View more	-	28 Aug 2020
ISTH2020	Not Applicable	-	26	Praxbind 5g	kcryobwtun(ucwtewdlge) = aznksehrfn rafwujyykr (rdvokgfxdm )	-	12 Jul 2020
ISTH2020	Not Applicable	-	26	Praxbind 2.5g	kcryobwtun(ucwtewdlge) = rtdsvdkydm rafwujyykr (rdvokgfxdm )	-	12 Jul 2020
ISTH2020	Not Applicable	-	7	Idarucizumab	(yyzhlyhpac) = abficzasol kggrvahgxg (bphtccfxxj )	-	12 Jul 2020
NCT02946931 (Pubmed)	Not Applicable	-	262	Idarucizumab	ddyxnsrtcr(dmwrmaiglb) = eiycelottj ymfspqfato (gzvlzhypfo )	-	01 Jun 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis